ProCE Banner Activity

New Long-Acting Options for Heavily Treatment–Experienced People With HIV-1

Clinical Thought

Lenacapavir is from a new drug class and may be a promising component of antiretroviral therapy if adherence can be ensured.

Released: January 05, 2023

Expiration: January 04, 2024

No longer available for credit.

Share

Faculty

Melissa Badowski

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP

Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP

Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP, has no relevant financial relationships to disclose.